A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis
Australian and New Zealand Journal of Obstetrics and Gynaecology · 2024
DOI: 10.1111/ajo.13804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2024. Verfasst von Andrew Proudfoot und 4 weiteren Autor:innen. Beteiligte Einrichtung: NICM Health Research Institute, Western Sydney University, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Endometriosis, Medical Marijuana, Cannabinoids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
People with endometriosis use cannabis to manage their symptoms. This study aimed to identify costs, modes of administration, product composition, and self‐reported effectiveness for those accessing medicinal cannabis in Australia. There were 192 survey responses analysed. Most (63.5%) used a ‘cannabis clinic’ doctor, incurring an initial consultation cost of $100–$200+ (10.2% Medicare bulk‐billed) and median cannabinoid medicine costs of $300AUD per month. Cost was a major barrier to access, necessitating reducing dosage (76.1%) and/or consuming illicit cannabis (42.9%), despite a prescription. Most (77%) medical consumers used two or more cannabis products, with delta‐9‐tetrahydrocannabinol predominant oil and flower products most frequently prescribed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NICM Health Research Institute, Western Sydney University, Sydney, New South Wales, Australia.
- School of Business, Western Sydney University, Sydney, New South Wales, Australia.
- School of Clinical Medicine, Health and Medicine, University of New South Wales, Sydney, New South Wales, Australia.
- Gynaecological Research and Clinical Evaluation (GRACE) Unit, Royal Hospital for Women, Sydney, New South Wales, Australia.
- Prince of Wales Private Hospital, Sydney, New South Wales, Australia.
- Medical Research Institute of New Zealand (MRINZ), Wellington, New Zealand.
ORCID-Profile: Andrew Proudfoot, Jason Abbott, Mike Armour
Zitieren
APA
Proudfoot, A., Duffy, S., Sinclair, J., Abbott, J., & Armour, M. (2024). A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.13804
Vancouver
Proudfoot A, Duffy S, Sinclair J, Abbott J, Armour M. A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2024. doi:10.1111/ajo.13804
BibTeX
@article{Proudfoot2024,
author = {Proudfoot, Andrew and Duffy, Sarah and Sinclair, Justin and Abbott, Jason and Armour, Mike},
title = {A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis},
journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
year = {2024},
doi = {10.1111/ajo.13804}
}
EUVIMED